The program designed to keep Chinese researchers from obtaining US national security secrets was chilling critical research and targeting Asian professors, critics say.
The program designed to keep Chinese researchers from obtaining U.S. national security secrets was chilling critical research and targeting Asian professors, critics say.
Regulus Announces Addition to Board of Directors
News provided by
Share this article
LA JOLLA, Calif., Jan. 27, 2021 /PRNewswire/
Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced Alice S. Huang, Ph.D. has been appointed to the Company s board of directors. Concurrently with her appointment to the Board, Dr. Huang was appointed to serve on the Compensation Committee. We are pleased to add Dr. Huang to the Regulus board. We believe her extensive scientific background will be of benefit to helping direct the Company s drug discovery and development programs, said Stelios Papadopoulos, Ph.D., Chairman of the Board of Directors of Regulus.